XML 97 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)
$ in Millions
1 Months Ended
Nov. 30, 2021
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Nov. 19, 2021
USD ($)
Dec. 31, 2020
USD ($)
Jan. 16, 2020
USD ($)
Business Acquisition [Line Items]            
Goodwill   $ 21,204 $ 21,264   $ 18,882  
Acceleron Pharma Inc.            
Business Acquisition [Line Items]            
Cash and cash equivalents       $ 340    
Investments       285    
In-process research and development (IPR&D)       6,380    
Products and product rights - Reblozyl (12 year useful life)       3,830    
Estimated useful life of intangible assets, acquired 12 years          
Deferred income tax liabilities       (1,814)    
Other assets and liabilities, net       82    
Total identifiable net assets       9,103    
Goodwill       2,411    
Consideration transferred       $ 11,514    
Acceleron Pharma Inc. | Measurement Input, Discount Rate            
Business Acquisition [Line Items]            
Present value discount rate       0.075    
Discount rate       0.060    
ArQule            
Business Acquisition [Line Items]            
Cash and cash equivalents           $ 145
In-process research and development (IPR&D)           2,280
Identifiable intangible assets           80
Deferred income tax liabilities           (361)
Other assets and liabilities, net           34
Total identifiable net assets           2,178
Goodwill           512
Consideration transferred           $ 2,690
ArQule | Measurement Input, Discount Rate            
Business Acquisition [Line Items]            
Present value discount rate           0.125